Factors Influencing Bioavailability: First-Pass Elimination

When an orally administered drug is absorbed across the GI tract, it flows through the portal vein into the liver before entering systemic circulation. The liver metabolizes the drug, and some metabolism also occurs in the gut wall. This first-pass metabolism substantially reduces the amount of drug reaching systemic circulation, directly lowering bioavailability compared to intravenous administration.

Drugs that are chemically unstable in stomach pH or susceptible to enzymatic degradation break down in the GI tract before absorption occurs. This chemical instability reduces the amount of intact drug available for absorption, significantly decreasing bioavailability. Protecting drugs from degradation through formulation strategies is essential for maintaining therapeutic effectiveness.

Highly hydrophobic drugs cannot dissolve in aqueous body fluids, limiting their absorption. Conversely, highly hydrophilic drugs cannot cross the lipid bilayer of cells, resulting in poor absorption. Optimal solubility allows drugs to dissolve adequately while crossing cell membranes through drug absorption mechanism passive membrane transport, directly influencing bioavailability.

Reducing drug particle size increases surface area for dissolution. Using a drug's salt, crystal, or hydrate form improves solubility and dissolution rates. Adding enteric coatings protects drugs from stomach degradation and allows release in the intestine. These formulation modifications enhance drug dissolution and absorption, thereby increasing bioavailability.

The liver is the primary site for first-pass metabolism of orally administered drugs, though some metabolism also occurs in the gut wall. This hepatic metabolism is the most prominent factor influencing bioavailability, as it significantly reduces the quantity of unchanged drug reaching systemic circulation after oral administration.

Orally absorbed drugs flow through the portal vein directly to the liver before entering systemic circulation. This hepatic-first route exposes drugs to extensive metabolism before they reach the general circulation. The portal vein pathway is fundamental to understanding why oral bioavailability is often lower than other administration routes.

Beyond first-pass metabolism, bioavailability depends on chemical stability, drug solubility, and formulation. Drugs must remain chemically stable in the GI tract, possess appropriate solubility for dissolution and absorption, and be formulated to optimize these properties. These interconnected factors collectively determine the fraction of an oral dose reaching systemic circulation.